Janssen-Cilag received approval from the European Commission for Stelara (ustekinumab) for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (psoralen plus ultraviolet A light). The approval is based on data from two Phase III, randomized, double-blind, placebo controlled trials involving nearly 2,000 patients. The studies show that treatment with Stelara, the fir...